Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.64 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.64 |
| ▸ | FPR2 | P25090 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | FPR1 | P21462 | 1/20 | 0.63 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.62 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALPL | P05186 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674103 | 0.91 | NPC1 (0.55) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL30406237 | 0.88 | NPC1 (0.69) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2554433 | 0.88 | NPC1 (0.69) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4678921 | 0.82 | MAPT (0.70) | CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL4674283 | 0.82 | POLB (0.69) | NPC1RAB9AMAPTALDH1A1POLB | |
| SCHEMBL4675291 | 0.81 | NPC1 (0.53) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4675296 | 0.81 | NPC1 (0.53) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4675197 | 0.80 | POLB (0.51) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5391948 | 0.80 | CYP1A2 (0.76) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27203365 | 0.80 | NPC1 (0.67) | NPC1RAB9ACYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | claimed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | claimed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | claimed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | claimed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | claimed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | NPC1 1554/4885RAB9A 4830/4885CYP1A2 3092/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | NPC1 1767/4885RAB9A 4813/4885CYP1A2 1301/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | NPC1 1767/4885RAB9A 4813/4885CYP1A2 1301/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | NPC1 1767/4885RAB9A 4813/4885CYP1A2 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.